Drug Trial Radar · NCT01077843
Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)
Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27,381
Actual
Start
Aug 17, 2009
Primary completion
Jul 1, 2015
Study completion Jul 1, 2015
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Mar 1, 2010
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a population-based cohort of patients with ankylosing spondylitis (AS) from general medical practices in the UK, France, and Germany with a nested case control component to assess associations between drug exposures of interest and clinical outcomes relevant to patients using cyclooxygenase-2 (COX-2) inhibitors / nonsteroidal anti-inflammatory drugs (NSAIDS). The main objective of the study is to describe in European participants with AS: 1) the use of etoricoxib 2) characteristics of those who use etoricoxib. 3) the safety profile of etoricoxib and other anti-inflammatory therapies with respect to specific clinical outcomes of interest relative to non-use of these medications and relative to each other.
Conditions
- Ankylosing Spondylitis
Interventions
EtoricoxibDrug
Cox-2 inhibitor
Other Cox-2 inhibitorsDrug
Cox-2 inhibitor
Other Non-selective NSAIDsDrug
Non-selective NSAID
No anti-inflammatory treatmentOther
No anti-inflammatory prescription
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate of gastrointestinal ulcer, perforation or bleedingTime frame: First incident event for a given patient through 31-December-2017
- Incidence rate of fatal or non-fatal acute myocardial infarction or unstable angina pectorisTime frame: First incident event for a given patient through 31-December-2017
- Incidence rate of fatal or non-fatal ischemic stroke, or transient ischemic attackTime frame: First incident event for a given patient through 31-December-2017
- Incidence rate of fatal or non-fatal hemorrhagic strokeTime frame: First incident event for a given patient through 31-December-2017
- Incidence rate of deep venous thrombosis, pulmonary embolism, or peripheral arterial embolism or thrombosisTime frame: First incident event for a given patient through 31-December-2017
- Incidence rate of acute renal impairment or failureTime frame: First incident event for a given patient through 31-December-2017
- Incidence rate of hypertensionTime frame: First incident event for a given patient through 31-December-2017
- Incidence rate of congestive heart failure or left ventricular dysfunctionTime frame: First incident event for a given patient through 31-December-2017
- Incidence rate of sudden or unexplained deathTime frame: First incident event for a given patient through 31-December-2017
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.